Magnetic precision: Unleashing the therapeutic potential of paclitaxel-loaded nanoparticles in breast cancer treatment

• Published in: Oral oncology reports Vol. 10; p. 100283
• Main Authors: Shobhana, N., Naveen, N Raghavendra, Goudanavar, Prakash
• Format: Journal Article
• Language: English
• Published: Elsevier Ltd 01.06.2024
• Subjects: Apoptosis; Breast cancer; Cytotoxicity; Magnetic nanoparticles; Paclitaxel; Cytotoxicity; Breast cancer; Magnetic nanoparticles; Paclitaxel; Apoptosis
• ISSN: 2772-9060; 2772-9060
• DOI: 10.1016/j.oor.2024.100283

Breast cancer remains a formidable global health challenge, necessitating innovative therapeutic strategies. In this context, our investigation delves into the potential of paclitaxel-loaded magnetic nanoparticles (MNPs) as a targeted and effective therapeutic approach for breast cancer. With its high incidence and significant impact on morbidity and mortality, breast cancer necessitates novel treatment modalities to enhance therapeutic outcomes and mitigate systemic toxicity associated with conventional chemotherapeutic agents. This study employs a comprehensive methodology encompassing various in vitro characterizations, cytotoxicity assessments, cellular uptake studies, in vivo experiments, and pharmacokinetic analyses to systematically evaluate the efficacy of paclitaxel-loaded MNPs. Our findings reveal that paclitaxel-loaded MNPs exhibit superior cytotoxicity, enhanced cellular uptake, and the induction of apoptosis compared to free paclitaxel. In vivo investigations further demonstrate notable tumor shrinkage and improved hematological parameters, indicating reduced systemic toxicity. However, pharmacokinetic evaluations underscore the need for refinement in this promising therapeutic approach. This research accentuates the potential of paclitaxel-loaded MNPs as a compelling candidate for breast cancer treatment, emphasizing the imperative for ongoing investigation and rigorous clinical validation. The integration of targeted nanocarrier systems into breast cancer therapy represents a promising avenue for advancing precision medicine and improving patient outcomes. •Paclitaxel-loaded magnetic nanoparticles (MNPs) offer a targeted and effective therapeutic approach for breast cancer treatment, addressing the need for innovative strategies to combat this global health challenge.•Comprehensive in vitro characterizations, cytotoxicity assessments, cellular uptake studies, in vivo experiments, and pharmacokinetic analyses were conducted to evaluate the efficacy of paclitaxel-loaded MNPs systematically.•Results demonstrate superior cytotoxicity, enhanced cellular uptake, and induction of apoptosis by paclitaxel-loaded MNPs compared to free paclitaxel, highlighting their potential as a promising treatment modality.•In vivo investigations show notable tumor shrinkage and improved hematological parameters, indicating reduced systemic toxicity associated with paclitaxel-loaded MNPs.•Despite promising results, pharmacokinetic evaluations suggest the need for refinement in this therapeutic approach, emphasizing the importance of ongoing investigation and rigorous clinical validation to advance precision medicine in breast cancer therapy.